AI-based clinical decision support tools support more proactive care and increased physician productivity from Equum and CLEW join forces on telehealth services in acute critical care
To improve the efficiency of the European healthcare system, the innovative CLEWICU solution identifies patients with an increased likelihood of being diagnosed with respiratory failure or hemodynamic instability, prioritizes workflow and treatment, and optimizes the allocation of critical care resources from CLEW Registered for CE Expanding its Commercial Reach in the European market
The highly experienced healthcare executives will advise CLEW Medical as the company expands its product offering in North America following FDA 510k approval from Healthcare industry professionals Ron Greeno and Mike Murphy join CLEW Medical’s Advisory Board
CLEW trained its AI using data on nearly 100,000 patients in ICUs. The AI-based algorithms are machine-learning models trained to predict such problems hours in advance. The product, CLEW-ICU, integrates care delivered by local and remote teams. According to the vendor, this clearance is the FDA’s first for technology in this category. from Healthcare IT Today FDA Approves Use of AI Tool Predicting Adverse Events In ICU
The healthcare technology revolution: AI-assisted doctors CLEWICU is the industry’s first-ever cleared device for predicting the likelihood of patient deterioration up to 8 hours in advance based on hemodynamic instability, enabling earlier evaluation and subsequent care plans. from HHM Global: CLEW Medical receives FDA approval for AI-based tech to support adult ICU patient assessment
The artificial intelligence ICU solution monitors and categorizes patient risk levels, helping providers identify patients whose health conditions are likely to deteriorate from HITInfrastructure: FDA Approves CLEW Medical’s Artificial Intelligence ICU Solution
A new artificial intelligence (AI) based ICU solution for predicting the likelihood of patient deterioration up to eight hours in advance has become the industry’s first ever device to receive clearance from the US Food and Drug Administration (FDA). from HospiMedica: AI-Based ICU Solution for Predicting Patient Deterioration Becomes Industry’s First Ever Device to Receive FDA Clearance
Developed by CLEW, the system gathers data from electronic health records, vital sign monitors and connected ICU devices, and uses machine learning models to calculate each person’s risk of their heart and blood flow becoming unstable. from FIERCE Biotech: CLEW’s AI cleared for predicting ICU patient decline
The U.S. FDA granted 510(k) clearance for Clew Medical Ltd.’s artificial intelligence (AI)-based solution that can predict hemodynamic instability in ICU patients eight hours in advance of deterioration. The system continuously monitors and stratifies patients by risk level to enable optimization of ICU resources. from BioWorld: Clew Medical receives FDA clearance for ICU device that predicts hemodynamic instability
CLEW Medical’s ICU tool uses machine learning models to identify patients whose conditions are likely to deteriorate. from EMR Industry FDA issues landmark clearance to AI-driven ICU predictive tool
"*" indicates required fields